All articles tagged with #cellectis
AstraZeneca is collaborating with and investing in French biotech Cellectis, paying a total of $105 million to acquire a 22% stake and 21% of voting rights. The deal includes a $25 million upfront payment and an $80 million equity investment, allowing AstraZeneca to add a non-voting observer to Cellectis' board. This move strengthens AstraZeneca's cell and gene therapy potential.
Cellectis has announced a strategic collaboration and investment agreements with AstraZeneca. The collaboration aims to develop up to 10 novel cell and gene therapy candidate products in areas of high unmet need, such as oncology, immunology, and rare diseases. AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities. Cellectis will receive up to $245 million in cash, including an upfront payment of $25 million, potential milestone payments, and tiered royalties. AstraZeneca will also make an initial equity investment of $80 million and potentially an additional investment of $140 million.